Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. At Delcath, we look beyond the ordinary and strive for excellence in all that we do. Our investigational product, HEPZATO™ KIT (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver, while controlling systemic exposure and associated side effects. We have the potential to change the lives of people with rare and life-threatening cancers of the liver with an innovative approach to drug-delivery. To date, over 1,000 treatments in Europe have been conducted, in both the commercial and clinical setting.
Company details
Find locations served, office locations
- Business Type:
- Service provider
- Industry Type:
- Clinical Services
- Market Focus:
- Nationally (across the country)
About Us
Our medical device is CE Marked in Europe since 2012 and sold under the trade name CHEMOSAT®. In prior research, our treatment has outperformed best available therapies and there are many exciting and near-term clinical developments. There is potential to expand the number of people we serve for years to come.
To deliver breakthroughs in therapies for the treatment of patients with primary and metastatic cancers to the liver through the use of novel isolation, saturation and filtration to improve clinical outcomes for patients while reducing drug-related side effects.